Alvarez Jean G Bustamante, Otterson Gregory A
Division of Medical Oncology, Department of Internal Medicine, The James Cancer Center and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Drugs Context. 2019 Mar 13;8:212566. doi: 10.7573/dic.212566. eCollection 2019.
mutations are seen in up to 3.5-4% of the non-small cell lung cancer (NSCLC) patients. mutations account for 50% of these cases, and the remaining mutations are non-V600E. The biologic behavior of -mutated lung tumors tends to be more aggressive and resistant to chemotherapy, but responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another effective tool to attain better response rates when compared to cytotoxic chemotherapy. New strategies such as immunotherapy are becoming as well another option to treat in the second-line setting patients with -mutated NSCLC.
在高达3.5%-4%的非小细胞肺癌（NSCLC）患者中可发现突变。其中，V600E突变占这些病例的50%，其余突变是非V600E突变。BRAF突变的肺肿瘤的生物学行为往往更具侵袭性且对化疗耐药，但与细胞毒性化疗相比，使用酪氨酸激酶抑制剂（如BRAF抑制剂，联合或不联合MEK抑制剂）可提供另一种有效手段以获得更高的缓解率。免疫疗法等新策略也正成为二线治疗BRAF突变NSCLC患者的另一种选择。
